All > Liver Fibrosis > Hepatocellular Carcinoma

Trans-arterial tirapazamine embolization for Liver Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Liver Cancer+3 MoreTrans-arterial tirapazamine embolization - CombinationProduct
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for liver cancer that involves using a PD-1 checkpoint inhibitor drug after Trans-arterial Tirapazamine Embolization (TATE) treatment.

Eligible Conditions
  • Liver Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Stomach Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Lumason®
1
CDK-004
1
Axitinib 5 MG

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: through study completion, an average of 3 years

Year 3
Overall survival
up to 24 months
Duration of Response
Overall Response Rate
Overall Response rate
Progression Free Survival
Response rate
Time to Progression

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Lumason®
1
CDK-004
1
Axitinib 5 MG

Trial Design

6 Treatment Groups

Hepatocellular carcinoma
1 of 6
Metastatic Gastro-esophageal cancer
1 of 6
Colorectal cancer
1 of 6
Gastric cancer
1 of 6
NSCLC
1 of 6
Advanced Hepatocellular carcinoma
1 of 6

Experimental Treatment

54 Total Participants · 6 Treatment Groups

Primary Treatment: Trans-arterial tirapazamine embolization · No Placebo Group · Phase 2

Hepatocellular carcinomaExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Metastatic Gastro-esophageal cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Nivolumab Injectable Product · Intervention Types: CombinationProduct, Drug
Colorectal cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Gastric cancerExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
NSCLCExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Opdivo Injectable Product or Keytruda Injectable Product · Intervention Types: CombinationProduct, Drug
Advanced Hepatocellular carcinomaExperimental Group · 2 Interventions: Trans-arterial tirapazamine embolization, Nivolumab Injectable Product · Intervention Types: CombinationProduct, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 3 years

Who is running the clinical trial?

Teclison Ltd.Lead Sponsor
3 Previous Clinical Trials
294 Total Patients Enrolled
Nadine Abi-Jaoudeh, MDPrincipal InvestigatorUC Irvine Medical Center
4 Previous Clinical Trials
385 Total Patients Enrolled
1 Trials studying Liver Cancer
186 Patients Enrolled for Liver Cancer

Eligibility Criteria

Age 18 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have Child-Pugh scores of 5-7.
You have a confirmed diagnosis of advanced HCC or metastatic gastric cancer.
Patients with HCC should have progressive disease (PD) on the first line immune therapy for advanced HCC
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top